# Implementation Plan: Enterprise Product Strategy, Innovation & Roadmap Management

**Branch**: `043-product-strategy-innovation-management` | **Date**: 2026-07-23 | **Spec**: [spec.md](./spec.md)

**Input**: Feature specification from `/specs/043-product-strategy-innovation-management/spec.md`

## Summary

This feature builds the enterprise Product Strategy, Innovation, Roadmap & Portfolio Management platform described in Volume 14 Part 2 Chapter 10: a 14-phase Product Operating Model and a 14-stage Product Lifecycle (Vision→Archive), organized under a 9-level Product Hierarchy (Business Unit → Product Portfolio → Product → Product Module → Feature → Epic → User Story → Task → Subtask) providing complete strategic-to-execution traceability; Product Vision/Mission Management with a hard vision-approval gate before roadmap or investment eligibility; Strategic Product Goals and Product OKR Management; Value Proposition and Positioning Management; Product Success Metrics; a Product Governance Framework (12 configurable roles, 8 governance workflows); Enterprise Innovation Management with a 14-stage innovation lifecycle, Idea Management, an Idea Priority Score gated behind mandatory Customer Validation, an Opportunity Backlog, Product Discovery, a searchable Experiment Repository, and Innovation Governance; Roadmap Planning (12 roadmap types, 8-level roadmap hierarchy) and Release Readiness gating (8-item checklist); Initiative, Epic, and Feature Management; Dependency Management and AI Capacity Planning (with Burnout Indicators); Product Portfolio Management and a 10-stage Investment lifecycle ending in Benefit Tracking and Closure; Product Financial Planning and Risk Management (5-level risk matrix); Strategic Execution Management; and a composite, administrator-weighted Product Health Score.

This chapter is not directly named by the constitution, but it self-applies **Article II** three times in its own FR text — FR-006 ("final strategic approval MUST always remain with authorized human decision-makers"), FR-021 (OKR AI recommendations require human approval), and FR-079 (AI Risk Intelligence outputs are reviewable/auditable, not autonomous) — more distinct FR-level Article II citations than any prior feature except `040`. It also self-applies **Article VII** twice (FR-027's 12 configurable Product Governance roles, FR-086's RBAC-governed strategic/innovation/roadmap/portfolio/financial/risk access).

Spec.md's own Assumptions flag a significant, unresolved scope question worth restating prominently here rather than silently narrowing it during planning: although filed under "Volume 14 Part 2 – Enterprise Marketing Data & Intelligence," this chapter's actual content (Product Vision, Innovation Pipeline, Roadmap, Portfolio, Investment, Risk, Product Health Score) describes a **general-purpose Product Operating System applicable to every TBT product, membership, course, community, and AI capability** — not a marketing-specific capability. Spec.md assumes platform-wide scope (consistent with the chapter's own stated Vision, "the strategic brain of the entire TBT product ecosystem," and its CEO/Executive-Leadership/CPO primary-user list) but flags this with `[NEEDS CLARIFICATION]` rather than asserting it as settled. This plan preserves that open question rather than resolving it by implementation-time assumption.

## Ownership & Dependency Analysis

Per this session's established practice, this feature's Key Entities and Assumptions were checked against the most-likely-overlapping prior features' actual `plan.md`/`spec.md` files before writing Project Structure.

### §1. Platform-wide scope vs. Volume 14's marketing-specific chapters — preserved NEEDS CLARIFICATION, not resolved

Spec.md's own Assumptions already flag this (see Summary above) rather than silently deciding it. This plan does not resolve it either: whether this chapter's Product Roadmap/Portfolio/Investment/Risk machinery governs decisions for Volumes 01–13 and all of Volume 14, or only for initiatives originating within Volume 14's own marketing roadmap, remains an open question for a future platform-wide architecture review (per `073-enterprise-platform-blueprint-roadmap`, the capstone synthesis chapter). The Project Structure below is written assuming platform-wide scope (matching spec.md's stated assumption) but this MUST be confirmed before cross-Wave implementation begins.

### §2. Campaign Management (`018`) — clean, confirmed

Spec.md's own Assumptions state a Product Roadmap Item referencing a marketing-related Feature links to, not replaces, `018`'s Campaign Registry record. Checked against `018`'s actual plan.md Summary: `018` owns campaign lifecycle/scheduling/approval/version-control as its own operational engine and makes no claim over a "Roadmap" or "Product Hierarchy" entity — no collision found. This chapter's Roadmap/Initiative/Epic/Feature records may reference a `018` Campaign as a linked artifact but do not redefine it.

### §3. Layered RBAC vs. `016` — reuse decision made explicit

Spec.md cites Constitution Article VII generically (FR-027, FR-086) but does not explicitly state that this chapter's 12 Product Governance roles, 11 Innovation Governance roles, and executive approval chains should be implemented as configured instances of `016`'s existing layered RBAC model (Organization → Department/Team → Role → Permission Group → Permission) rather than a new, parallel role system. Consistent with the reuse chain established for every governance-heavy feature since `016` itself (`018`, `022`, `027`, `028`, `033`, `042`), this plan makes that reuse decision explicit: `043` configures role/permission/approval-chain instances on top of `016`'s model; it does not define a second RBAC engine.

### §4. Competitive Intelligence (`042`) — new finding, closes a one-directional forward reference

`042-competitive-intelligence-market-research`'s own spec.md Assumptions forward-declare this exact boundary: "`043` is assumed to own Product Roadmap execution; this spec's Opportunity Identification and Gap Analysis outputs are assumed to hand off *recommendations* into that feature's roadmap-planning workflow rather than this platform directly managing the product roadmap itself." `043`'s own spec.md does not reciprocally acknowledge `042` by name (it mentions `042` only once, regarding shared §42 governance/security boilerplate), but its FR text needs the relationship: FR-003 lists "Competitive Intelligence" among the data sources strategic product decisions must be based on, and FR-038 (Opportunity Backlog) explicitly lists "Competitor Intelligence" and "Market Research" among its 10 sourcing inputs.

**Ownership decision**: `042` remains the canonical owner of competitor/market/trend/opportunity/threat intelligence generation. `043` consumes `042`'s Opportunity, Trend, and Gap Analysis outputs as Opportunity Backlog source inputs and as Strategic Analysis data feeding roadmap/portfolio decisions; `043` does not re-run competitive analysis or re-detect market opportunities independently. This closes the one-directional forward reference `042` left open, mirroring the same pattern found between `041` and `042` last turn.

### §5. Product Health Score vs. the Customer Health Score cluster — confirmed no collision

Checked against the session's ongoing four/five-way "Customer Health Score" collision (`019`, `034`, `035`, `040`, referenced via `029`): `043`'s **Product Health Score** (FR-083, composite of Customer Satisfaction, Growth, Financial Performance, Operational Stability, Strategic Alignment, Innovation Progress, Quality Indicators) is a **product-level**, not customer-level, composite score, structurally and semantically distinct from every "Customer Health Score" instance in the cluster. No new entry is added to that cluster, and this chapter does not reference or attempt to compute a customer-level score.

### §6. Preserved NEEDS CLARIFICATION items (from spec.md's own Edge Cases — not resolved here)

- Duplicate/resubmission detection when a rejected idea is resubmitted in substantially similar form (Edge Cases; only a manual "merge duplicate submissions" feature is defined).
- Circular-dependency detection/resolution rule in Dependency Management (Edge Cases; FR-063–064 do not define one).
- Evidence/linkage requirement (vs. a manually toggled checkbox) for Release Readiness Checklist item completion (Edge Cases).
- Whether Capacity Planning's Burnout Indicators/Overtime Risk function as a binding gate on roadmap approval or remain purely advisory (Edge Cases; spec.md's own Assumptions lean toward advisory-only, unlike the Vision/Validation/Release Readiness gates, but this is not stated definitively by the source).
- Whether a persistently low OKR Key Result Confidence Level with an acceptable Progress Percentage triggers automatic AI escalation or requires human noticing (Edge Cases).
- Arbitration rule when two Product Portfolios' investment requests jointly exceed Business-Unit-level Budget Allocation (Edge Cases).
- Whether a High/Critical risk record without a Mitigation Strategy/Contingency Plan is blocked from saving or merely flagged non-compliant, despite FR-078's "mandatory" language (Edge Cases).
- Cascading behavior for descendant Roadmap Items/Epics/Initiatives when their Product Vision is later Archived (Edge Cases).
- Reconciliation rule when a Discovery Review approval is later contradicted by a "Major Revisions Required" Customer Validation outcome for the same initiative (Edge Cases).
- Whether AI-vs-human Innovation/Priority Score disagreement is flagged for explicit reconciliation or simply displayed side by side (Edge Cases).

None of these are silently resolved; each remains an open gate for a future clarification pass.

## Technical Context

**Language/Version**: TypeScript 5.x (backend, web), Dart 3.x (mobile) — consistent with 001–042.

**Primary Dependencies**: NestJS, Next.js; `016`'s layered RBAC model for all 12 Product Governance and 11 Innovation Governance roles (per §3); `042`'s Opportunity/Trend/Gap Analysis outputs as Opportunity Backlog and strategic-decision inputs (per §4); `008`'s AI gateway for AI-assisted prioritization, risk analysis, roadmap recommendations, resource planning, forecasting, opportunity detection, and Product Health analysis (FR-006).

**Storage**: PostgreSQL (29 entities per Key Entities: Business Unit, Product Portfolio, Product, Product Module, Feature, Epic, User Story/Task/Subtask, Product Vision, Product Mission, Strategic Product Goal, OKR Objective/Key Result, Value Proposition, Positioning Framework, Idea, Opportunity, Discovery Initiative, Customer Validation Record, Experiment, Innovation Governance Record, Roadmap/Roadmap Item, Initiative, Release, Dependency, Capacity Plan, Investment, Risk Record, Product Health Score, KPI/Success Metric, Audit Log Entry — the largest entity count of any feature planned this session).

**Testing**: Jest (backend — three Foundational contract tests matching this spec's own highest-stakes Success Criteria: vision-approval-gates-roadmap-and-investment for SC-001, idea-priority-score-gated-behind-validation for SC-002, and release-readiness-blocks-deployment-without-override for SC-004), Playwright (web e2e — 9-level Hierarchy Explorer, Vision/Mission workspace, Innovation Pipeline board, Roadmap view, Executive Portfolio Dashboard).

**Target Platform**: Web (Executive/Admin Portal, rendered inside `017`'s workspace shell).

**Performance Goals**: Per FR-088, the platform must support enterprise-scale product portfolios and historical data volumes while keeping dashboards responsive, with background processing not degrading operational workloads [NEEDS CLARIFICATION: no numeric thresholds stated in source, consistent with spec.md's own Assumptions that this chapter does not define numeric performance targets the way some other Volume 14 chapters do].

**Constraints**: Zero products with an active Roadmap Item or Investment record may lack an Approved, Active Product Vision (FR-013, SC-001); zero ideas may reach roadmap prioritization without a recorded Idea Priority Score and a Fully/Partially Validated Validation Decision or a logged executive override (FR-043, SC-002); zero releases reach deployment with an incomplete Release Readiness Checklist unless an authorized executive override is present and logged (FR-057, SC-004); zero High/Critical risks may lack a documented Mitigation Strategy and Contingency Plan (FR-078, SC-005); zero AI-generated recommendations across OKR/Capacity/Roadmap/Risk modules may change a target, resource, timeline, or priority without recorded human approval (FR-006, FR-021, FR-067, FR-079, SC-006; Constitution Article II); every investment reaching Closure must have Benefit Realization data comparable against its original ROI Estimate (FR-073, SC-007).

**Scale/Scope**: 29 entities, 89 FRs, 8 user stories, 14-phase Product Operating Model, 14-stage Product Lifecycle, 9-level Product Hierarchy, 14-stage Innovation Lifecycle, 10-stage Investment Lifecycle, 10 preserved NEEDS CLARIFICATION items (including the platform-wide-scope question preserved from spec.md itself), no worsening of any of the 8 previously-accumulated Wave 2/3 architecture gaps, one new cross-feature reuse relationship established with `042` (§4), and one explicit RBAC-reuse decision made with `016` (§3).

## Constitution Check

| Article / Section | Status | Notes |
|---|---|---|
| I. Server-Authoritative State | PASS | Idea Priority Score, Product Health Score, and all gating decisions (vision, validation, release readiness) are server-computed/server-recorded, never client-asserted. |
| II. AI Is Assistive, Never Autonomous | PASS — **self-applied 3× in FR text** | FR-006, FR-021, FR-079 each explicitly cite Article II; every AI-generated recommendation (OKR, capacity, roadmap, risk, Product Health analysis) requires recorded human approval before a target/resource/timeline/priority changes (SC-006). |
| III. No Dark Patterns, No Guaranteed-Outcome Claims | PASS | FR-008 bars automatic strategic-investment approval, automatic launch without approval, and overriding executive decisions. |
| IV. Historical Immutability | PASS | Product Vision, Idea, Investment, and Risk records maintain complete version history rather than overwriting prior states (FR-014, FR-035, FR-085). |
| V. Ledger-Based Internal Economies | N/A | This chapter has no internal balance/points/wallet construct. |
| VI. Consent Is First-Class, Per-Channel, and Versioned | N/A | This chapter's Customer Validation methods (interviews, surveys, betas) are assumed to inherit consent handling from `013`/`019`/`030`/`041`'s existing consent/participant-governance mechanisms rather than defining a new one; this chapter does not itself collect or store consent state. |
| VII. Layered, Explicit RBAC With Approval Chains | PASS — **self-applied 2× in FR text, reuse decision made explicit (§3)** | FR-027, FR-049, FR-086 configure Product/Innovation Governance roles and executive approval chains as instances of `016`'s layered RBAC model rather than a new engine. |
| VIII. No Pay-to-Win, No Vanity-Metric Optimization | PASS | Idea Priority Score, Opportunity prioritization, and Product Health Score are all evidence/data-based (FR-003, FR-034) rather than vanity-metric-driven. |
| IX. Action Before Consumption | PASS | Every innovation initiative and roadmap item progresses through defined stages/gates toward a measurable outcome (FR-009, FR-031), not passive tracking. |
| Localization & Language Requirements | PASS (not a focus of this chapter) | No Tamil/Tanglish-specific FR in this chapter; this is an internal executive/strategy tool, not a customer-facing surface. |
| Security & Compliance Baseline | PASS | FR-085–FR-087 (immutable audit logs, RBAC-governed access, encryption at rest/in transit, retention/archival policies) align with the baseline; assumed to sit within, not replace, the constitution's compliance baseline per spec.md's own Assumptions. |

## Project Structure

### Documentation (this feature)

```
specs/043-product-strategy-innovation-management/
├── spec.md
├── plan.md
├── research.md         # 10 NEEDS CLARIFICATION items from §6, incl. the §1 scope question
├── data-model.md        # 29 entities
├── quickstart.md         # 8 user-story validation walkthrough
└── contracts/
    ├── vision-approval-gates-roadmap-and-investment.contract.md
    ├── idea-priority-score-gated-behind-validation.contract.md
    └── release-readiness-blocks-deployment-without-override.contract.md
```

### Source Code (repository root)

```
backend/src/modules/product-strategy-innovation/
├── operating-model-lifecycle-hierarchy/    # FR-001-011 — 14-phase model, 14-stage lifecycle, 9-level hierarchy
├── vision-mission-management/              # FR-012-017 — vision approval gate, mission cadence review
├── goals-okr-value-positioning-metrics/    # FR-018-025 — goals, OKRs, value prop, positioning, success metrics
├── product-governance/                     # FR-026-028 — 12 roles, 8 workflows, reuses 016
├── innovation-pipeline-idea-management/    # FR-029-039 — idea repository, priority score, pipeline, opportunity backlog
├── product-discovery-customer-validation/  # FR-040-043 — discovery gate, validation decision gate
├── experiment-management-repository/       # FR-044-047 — experiment types, results, searchable repository
├── innovation-governance/                  # FR-048-050 — 11 roles, 10 workflows
├── roadmap-planning-release-readiness/     # FR-051-057 — roadmap hierarchy, release types, readiness checklist gate
├── initiative-epic-feature-management/     # FR-058-062 — initiatives, epics (11-stage), features, prioritization
├── dependency-capacity-planning/           # FR-063-068 — dependencies, capacity metrics, AI capacity forecasting
├── portfolio-investment-management/        # FR-069-074 — portfolio types, 10-stage investment lifecycle
├── financial-planning-risk-management/     # FR-075-079 — financial metrics, 5-level risk matrix, AI risk intelligence
└── strategic-execution-product-health/     # FR-080-084 — execution framework, composite Product Health Score
└── common/
    # reused from 016 (layered RBAC/approval chains), 008 (AI gateway),
    # 042 (Opportunity/Trend/Gap Analysis outputs — consumed, not recomputed),
    # 018 (Campaign Registry — referenced, not redefined)

web/app/(admin)/product-strategy/
├── hierarchy-explorer/
├── vision-mission/
├── goals-okr/
├── innovation-pipeline/
├── discovery-validation/
├── experiments/
├── roadmap/
├── initiatives-epics-features/
├── dependencies-capacity/
├── portfolio-investment/
├── financial-risk/
└── executive-performance/
```

**Structure Decision**: `operating-model-lifecycle-hierarchy` and `vision-mission-management` are built and contract-tested first — the hierarchy is the structural backbone every other module's traceability depends on, and the vision-approval gate is the first hard blocking gate the chapter defines (§11, restated in the Enterprise Acceptance Criteria). `innovation-pipeline-idea-management` and `product-discovery-customer-validation` follow immediately after, since Idea Priority Score gating behind Customer Validation is this chapter's central risk-reduction mechanism per spec.md's own User Story 3 rationale.

## Complexity Tracking

*No constitutional violations identified. This section intentionally left empty.*
